Rockland Immunochemicals Acquires Epi-Plus Antibody Product Line

Rockland Immunochemicals, Inc. (Gilbertsville, PA, USA), a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development, and preclinical studies, acquired the Epi-Plus antibody product line from 21st Century Biochemicals, Inc.

These are regarded the most well validated antibodies available for epigenetics research. All Epi-Plus (Littleton, CO, USA) antibodies are multiassay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP).

The global revenue market for epigenetics has been estimated at USD 2.6 billion in 2012 and is expected to reach USD 8 billion by 2017, a five-year Compounded Annual Growth Rate (CAGR) of 25%. Rockland will market the Epi-Plus product line on its e-commerce website and through its existing global distribution network.

Dr. Jordan Fishman, president and CSO of 21st Century Biochemicals said, “As 21st Century Biochemicals continues to focus its efforts on providing US manufactured custom peptide and antibody solutions for its customers, we are pleased that the Epi-Plus product line is a strong strategic fit for the Rockland portfolio.”

Rockland Immunochemicals has supported the academic, biopharma, and diagnostic industries with antibodies and antibody based tools for over 50 years. At its US based facilities, Rockland produces and distributes reagents suited for integration into various assays performed on different platforms including western blot (WB), immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA and FLOW cytometry. Additional information about Rockland’s products and services can be found on the company’s website.

Related Links:
Rockland Immunochemicals, Inc.
Epi-Plus